found
antibodi
ab
myelin
basic
protein
mbp
major
compon
antibodi
respons
multipl
sclerosi
ms
patient
recent
shown
igg
sera
ms
patient
activ
hydrolysi
mbp
howev
literatur
avail
data
concern
possibl
mbphydrolyz
ab
cerebrospin
fluid
csf
ms
patient
shown
averag
content
igg
sera
higher
csf
compar
first
time
averag
content
lambdaand
kappaigg
well
igg
four
differ
subclass
csf
sera
ms
patient
averag
rel
content
lambdaigg
kappa
igg
case
csf
sera
compar
csf
total
igg
respect
sera
decreas
differ
order
electrophoret
immunolog
homogen
igg
obtain
sequenti
affin
chromatographi
csf
protein
protein
gsepharos
fplc
gel
filtrat
present
first
evid
show
igg
csf
effici
hydrolyz
mbp
averag
specif
catalyt
activ
unpredict
higher
ab
sera
ms
patient
possibl
reason
find
discuss
suggest
antimbp
abzym
csf
may
promot
import
neuropatholog
mechan
chronic
inflammatori
disord
ms
pathogenesi
develop
citat
doronin
vb
parkhomenko
ta
castellazzi
padroni
pastor
et
al
comparison
antibodi
hydrolyz
myelin
basic
protein
cerebrospin
fluid
serum
patient
multipl
sclerosi
plo
one
artifici
abzym
catalyt
ab
transit
state
analogu
chemic
reaction
natur
abzym
novel
biolog
catalyst
attract
lot
interest
recent
year
review
artifici
abzym
abzym
analog
transit
state
catalyt
reaction
antiidiotyp
ab
induc
primari
antigen
may
show
featur
includ
catalyt
activ
review
also
see
past
two
decad
becom
clear
autoantibodi
autoab
sera
patient
differ
autoimmun
diseas
possess
enzymat
activ
occurr
distinct
featur
autoimmun
diseas
review
differ
abzym
may
play
signific
role
form
specif
pathogen
pattern
clinic
set
differ
autoimmun
condit
broaden
autoab
properti
patient
autoimmun
diseas
produc
ab
nucleoprotein
complex
dna
enzym
particip
nucleic
acid
metabol
autoimmun
diseas
spontan
induct
antiidiotyp
antibodi
ab
elicit
primari
antigen
includ
catalyt
activ
transit
polyreact
catalyt
activ
autoantigendirect
activ
natur
abzym
hydrolyz
dna
rna
polysaccharid
oligopeptid
protein
present
serum
patient
sever
autoimmun
viral
diseas
review
healthi
human
develop
abzym
detect
dnase
rnase
activ
level
usual
borderlin
sensit
detect
method
multipl
sclerosi
ms
chronic
demyelin
patholog
central
nervou
system
present
seriou
medic
social
problem
etiolog
remain
unclear
valid
theori
pathogenesi
assign
main
role
destruct
myelinproteolipid
shell
axon
inflamm
relat
autoimmun
reaction
ref
therein
although
tcell
immun
system
play
lead
role
ms
pathogenesi
normal
function
bcell
system
also
import
develop
diseas
enhanc
synthesi
immunoglobulin
usual
igg
free
light
chain
polyspecif
dna
bind
ab
interact
phospholipid
observ
ms
patient
shown
myelin
basic
proteincompon
ms
tissu
undergo
autocatalyt
cleavag
slightli
alkalin
ph
importantli
one
major
peptid
releas
contain
immunodomin
epitop
cleavag
reaction
inhibit
proteas
inhibitor
except
phenylmethanesulfonyl
fluorid
serin
proteas
inhibitor
recent
shown
myelin
basic
protein
mbp
hydrolyz
activ
intrins
properti
igg
igm
iga
sera
ms
patient
addit
shown
ms
igg
contain
lambda
ligg
kappa
kigg
light
chain
well
igg
four
subclass
effici
hydrolyz
mbp
recognit
degrad
mbp
peptid
serum
autoab
confirm
novel
biomark
ms
establish
ms
drug
copaxon
appear
specif
inhibitor
mbphydrolyz
abzym
activ
take
observ
account
analysi
rel
concentr
protein
mbphydrolyz
abzym
cerebrospin
fluid
csf
ms
patient
special
interest
present
studi
first
time
compar
rel
content
total
protein
ligg
kigg
well
igg
four
subclass
sera
csf
ms
patient
use
differ
approach
provid
first
time
strong
direct
evid
proteolyt
antimbp
activ
intrins
igg
csf
ms
patient
compar
paramet
character
csf
sera
ms
patient
fifteen
patient
women
men
satisfi
criteria
clinic
laboratorysupport
definit
ms
accord
retrospect
select
studi
relapsingremit
rr
primari
progress
pp
agreement
criteria
lublin
reingold
clinic
cours
rr
pp
clinic
activ
relaps
time
sampl
mri
activ
presenc
gadolinium
enhanc
lesion
mri
examin
analyz
describ
previous
characterist
ms
patient
summar
tabl
interest
compar
differ
index
csf
sera
ms
patient
therefor
first
measur
rel
concentr
total
protein
csf
sera
ms
patient
tabl
rel
concentr
total
protein
csf
rang
mgml
sera
mgml
fifteen
ms
patient
vari
differ
rang
averag
concentr
total
protein
serum
mgml
higher
compar
csf
mgml
valu
demonstr
good
correl
coeffici
correl
cc
tabl
rel
concentr
total
igg
serum
rang
mgml
averag
valu
mgml
higher
csf
rang
mgml
averag
valu
mgml
good
correl
valu
cc
interestingli
concentr
total
protein
csf
higher
total
igg
differ
case
serum
factor
approxim
lower
estim
rel
concentr
igg
contain
kappa
lambda
light
chain
serum
csf
rel
content
lab
sera
patient
compar
rang
total
ab
averag
valu
mgml
case
csf
remark
vari
rang
averag
valu
mgml
fig
good
correl
observ
cc
rel
content
kab
sera
significantli
higher
rang
averag
valu
mgml
similar
situat
observ
case
csf
rang
averag
valu
mgml
overal
rel
content
lab
total
ab
sera
approxim
statist
significantli
higher
content
kab
statist
significantli
lower
csf
next
step
compar
rel
content
csf
sera
fig
fig
differ
valu
sera
significantli
higher
variou
patient
tabl
biggest
differ
csf
sera
ab
observ
case
averag
content
sera
statist
significantli
lower
p
statist
significantli
higher
p
case
csf
fig
ms
patient
content
rang
averag
valu
mgml
rang
averag
valu
mgml
csf
differ
gener
content
differ
subclass
case
csf
sera
decreas
differ
order
case
csf
content
higher
sera
highest
content
observ
sera
csf
fig
data
summar
tabl
serum
antimbp
ab
sera
ms
patient
report
sever
articl
avail
data
autoab
csf
ms
patient
use
elisa
compar
rel
level
ab
mbp
sera
csf
ms
patient
seven
healthi
donor
rel
index
antimbp
ab
sera
test
patient
vari
averag
unit
fig
case
seven
healthi
donor
rel
index
antimbp
ab
vari
averag
valu
approxim
lower
ms
patient
data
agreement
previous
publish
result
accord
concentr
autoab
mbp
sera
healthi
donor
zero
chang
unit
averag
use
method
test
system
shown
index
antimbp
ab
csf
ms
patient
term
dilut
csf
serum
prepar
vari
unit
averag
unit
fig
could
estim
real
index
antimbp
ab
csf
seven
healthi
donor
sinc
valu
case
remark
differ
background
valu
thu
averag
rel
content
antimbp
ab
sera
ms
patient
approxim
higher
correspond
csf
time
rel
content
total
igg
sera
higher
csf
tabl
mean
csf
averag
approxim
deplet
ab
mbp
relat
total
amount
antibodi
compar
ratio
sera
good
correl
antimbp
csf
sera
cc
recent
demonstr
highli
purifi
igg
sera
ms
sle
patient
catalyz
hydrolysi
mbp
work
similarli
electrophoret
immunolog
homogen
igg
purifi
csf
sera
ms
patient
healthi
donor
sequenti
chromatographi
protein
asepharos
condi
tion
remov
nonspecif
bound
protein
follow
gel
filtrat
acid
buffer
destroy
immun
complex
homogen
csfigg
mix
serigg
mix
equal
amount
electrophoret
homogen
igg
prepar
csf
sera
denot
prepar
respect
csfigg
mix
serigg
mix
confirm
sdspage
silver
stain
show
singl
band
nonreduc
condit
two
band
correspond
heavi
light
chain
reduct
fig
csfigg
mix
serigg
mix
correspond
seven
healthi
donor
also
electrophoret
homogen
first
shown
individu
mix
igg
prepar
csf
csfigg
mix
sera
serigg
mix
effici
hydrolyz
mbp
see
electrophoret
homogen
csfigg
mix
use
prove
mbphydrolyz
activ
csfigg
mix
intrins
properti
ms
ab
appli
sever
known
rigid
criteria
import
criteria
given
electrophoret
homogen
csfigg
mix
serigg
mix
fig
b
fplc
gelfiltr
csfigg
mix
condit
acid
shock
ph
lead
disappear
activ
peak
proteolyt
activ
track
exactli
kda
igg
proteolyt
activ
absent
zone
correspond
molecular
mass
kda
known
canon
proteas
fig
c
complet
adsorpt
mbphydrolyz
activ
antiigg
sepharos
lead
disappear
catalyt
activ
solut
elut
adsorb
buffer
acid
ph
fig
similar
result
obtain
serigg
mix
shown
previous
igg
sera
healthi
donor
hydrolyz
mbp
csfigg
mix
serigg
mix
correspond
seven
healthi
donor
analyz
articl
also
catalyt
inact
fplc
gelfiltr
ab
mix
condit
acid
shock
affin
chromatographi
antiigg
sepharos
exclud
possibl
artifact
due
hypothet
trace
contamin
canon
enzym
csfigg
mix
serigg
mix
prepar
separ
sdspage
mbphydrolyz
activ
detect
extract
protein
separ
gel
slice
fig
known
canon
proteas
trypsin
chymotrypsin
chymotrypsinogen
etc
enzym
rel
low
molecular
mass
rel
easi
signific
restor
enzymat
activ
treatment
sd
sinc
sd
dissoci
protein
complex
electrophoret
mobil
usual
low
molecular
mass
proteas
kda
coincid
intact
igg
ab
complex
proteas
detect
proteolyt
activ
gel
region
correspond
intact
igg
csf
sera
provid
direct
evid
csf
serum
igg
contain
admixtur
canon
proteas
possess
mbphydrolyz
activ
addit
csfigg
mix
serigg
mix
correspond
seven
healthi
donor
also
inact
sdspage
electrophoresi
exampl
fig
shown
previous
polyclon
sle
ms
antimbp
igg
purifi
mbpsepharos
hydrolyz
mbp
mani
test
protein
similar
situat
observ
case
abzym
protein
peptid
revers
transcriptas
integras
human
serum
albumin
casein
thyroglobulin
intestin
vasoact
peptid
howev
igg
pool
sera
patient
sle
hivinfect
patient
separ
sorbent
bear
immobil
specif
protein
contain
small
fraction
abzym
hydrolyz
sever
variou
protein
includ
human
serum
albumin
casein
hiv
revers
transcriptas
integras
therefor
could
exclud
igg
csf
sera
ms
patient
contain
small
fraction
enzym
specif
hydrolyz
human
serum
albumin
casein
thyroglobulin
protein
time
find
sera
variou
patient
autoimmun
diseas
abzym
hydrolyz
sever
control
protein
hen
egg
lysozym
human
milk
lactalbumin
lactoferrin
therefor
three
protein
easili
cleavabl
canon
proteas
use
analysi
csfigg
mix
serigg
mix
substrat
specif
fig
show
csfigg
mix
effici
cleav
mbp
condit
remark
hydrolyz
three
control
protein
similar
result
obtain
serigg
mix
fig
known
classic
mammalian
bacteri
viral
proteas
mostli
unspecif
capabl
hydrolyz
protein
specif
bacteri
viral
protein
contrast
canon
proteas
ms
igg
specif
hydrolyz
mbp
control
test
protein
data
also
indic
igg
prepar
csf
sera
contain
impur
classic
human
bacteri
viral
proteas
known
due
altern
splice
cdna
anim
human
mbp
consist
sever
relat
form
differ
molecular
mass
kda
addit
mbp
may
partial
hydrolyz
human
cell
protein
purif
therefor
highli
purifi
prepar
mbp
usual
homogen
accord
sdspage
contain
sever
protein
band
kda
usual
major
studi
use
kda
mbp
contain
remark
amount
form
protein
first
rel
activ
csf
ab
mbp
cleavag
calcul
decreas
intens
coomassiestain
kda
mbp
band
electrophoresi
differ
intens
protein
incub
absenc
presenc
ab
use
calcul
quantit
estim
proteas
activ
found
low
concentr
igg
prepar
correspond
reaction
first
order
major
kda
mbp
fraction
convert
product
hydrolysi
within
linear
region
igg
concentr
exampl
fig
demonstr
data
csfigg
mix
time
cours
convers
exampl
fig
lane
tabl
ra
igg
sera
significantli
lower
igg
use
higher
concentr
mgml
depend
prepar
reaction
mixtur
incub
h
tabl
surpris
averag
specif
ra
igg
csf
higher
ab
sera
ratio
specif
ra
mbphydrolyz
igg
case
csf
serum
individu
patient
vari
rang
tabl
coeffici
correl
antimbp
hydrolyz
igg
csf
sera
posit
low
cc
antimbp
ab
titer
mbphydrolyz
activ
case
csf
sera
neg
also
low
analys
made
catalyt
activ
ab
csf
data
report
paper
provid
strong
evid
mbphydrolyz
activ
intrins
properti
igg
present
csf
ms
patient
due
copurifi
enzym
entri
none
patient
donor
symptom
infect
shown
csf
sera
well
igg
purif
contain
bacteri
contamin
electrophoret
homogen
csfigg
mix
serigg
mix
show
mbphydrolyz
activ
fplc
gelfiltr
condit
acid
shock
affin
chromatographi
antiigg
sepharos
sdspage
zone
correspond
intact
igg
activ
correspond
zone
canon
proteas
rel
low
molecular
mass
kda
fig
addit
contrast
canon
proteas
csfigg
mix
serigg
mix
hydrolyz
control
protein
hen
egg
lysozym
human
milk
lactalbumin
lactoferrin
fig
overal
abzym
ms
patient
may
significantli
activ
hydrolysi
mbp
found
tabl
previous
shown
us
fraction
abzym
differ
catalyt
activ
includ
proteas
one
serum
autoimmun
patient
usual
exceed
total
immunoglobulin
sinc
specif
activ
calcul
use
total
concentr
igg
specif
proteas
activ
individu
monoclon
subfract
polyclon
igg
pool
may
significantli
higher
nonfraction
igg
addit
repertoir
polyclon
ab
differ
antigen
case
sera
ms
patient
may
significantli
wider
csf
may
one
possibl
reason
lower
specif
activ
serum
igg
time
evergrow
number
observ
suggest
autoimmun
diseas
origin
defect
hematopoiet
stem
cell
recent
shown
specif
reorgan
immun
system
spontan
develop
profound
slelik
patholog
mrllprlpr
mice
associ
chang
differenti
profil
level
prolifer
bone
marrow
hematopoiet
stem
cell
product
dnase
atpas
amylas
abzym
immun
healthi
mice
dna
also
lead
product
ab
dnase
activ
howev
associ
increas
lymphocyt
prolifer
suppress
apoptosi
lymphocyt
differ
organ
especi
spleen
chang
differenti
bone
marrow
cell
thu
reason
suggest
bcell
csf
ms
patient
produc
ab
interact
mbp
also
specif
antimbp
abzym
high
proteolyt
activ
abzym
produc
lymphocyt
mbp
differ
organ
ms
patient
circul
blood
system
may
lower
mbphydrolyz
activ
comparison
antimbp
ab
csf
may
differ
ratio
abzym
antimbp
ab
without
catalyt
activ
csf
sera
ms
patient
reveal
high
correl
coeffici
differ
index
character
igg
csf
sera
ms
patient
thu
addit
question
good
correl
variou
index
character
differ
ms
patient
analysi
correl
titer
ab
dna
well
mbp
differ
standard
clinic
paramet
includ
poser
criteria
index
evalu
damag
function
system
pyramid
function
cerebellar
function
function
brain
stem
sensit
function
function
intestin
urinari
bladder
visual
function
cerebr
psychic
function
sum
characterist
case
patient
ms
carri
whole
group
ms
patient
absolut
valu
posit
cc
titer
antidna
antimbp
ab
clinic
poser
index
low
absent
even
neg
statist
nonsignific
sever
cc
becam
higher
reach
valu
divis
cohort
subgroup
patient
primari
progress
secondari
progress
remit
cours
diseas
group
primari
progress
remit
cours
secondari
progress
cours
ms
patient
homogen
respect
patient
characterist
subdivis
use
cluster
factori
analysi
reveal
high
statist
signific
correl
coeffici
exampl
one
subsubgroup
remit
cours
subgroup
direct
depend
titer
antimbp
symptom
lesion
pyramid
tract
could
observ
cc
case
correl
opposit
sign
observ
pair
analyz
paramet
three
subgroup
differ
ms
cours
subsubgroup
obtain
cluster
analysi
subgroup
absenc
definit
depend
titer
antidna
antimbp
ab
paramet
standard
clinic
indic
may
caus
sever
reason
ms
extrem
multifactori
diseas
similar
pathomorpholog
clinic
indic
manifest
ms
may
result
differ
underli
process
condit
exampl
ms
patient
rel
stabil
differ
organ
function
destruct
effect
transient
immun
system
error
significantli
differ
depend
genet
background
environment
stress
factor
includ
geograph
one
protein
influenza
herp
polyoma
epsteinbarr
virus
bacteria
report
mimic
human
myelin
protein
infect
therefor
lead
immun
protein
stimul
subsequ
format
ab
myelin
final
develop
autoimmun
reaction
individu
ms
patient
develop
autoimmun
reaction
stimul
differ
viral
bacteri
infect
well
variou
toxic
chemic
furthermor
also
taken
account
ms
patholog
least
two
phase
cascad
reaction
correspond
first
inflammatori
phase
complic
involv
mani
protein
enzym
cytokin
chemokin
induc
macrophag
cell
produc
n
radic
osteopathin
complex
coordin
action
tand
bcell
complement
system
inflamm
mediat
autoab
result
format
demyelin
nodi
interrupt
axon
conduct
neurodegen
phase
ms
ensu
thereaft
directli
connect
neural
tissu
destruct
patient
therefor
analysi
biochem
immunolog
clinic
indic
must
take
account
current
stage
diseas
obvious
quit
differ
characterist
patholog
process
obtain
individu
patient
diseas
progress
background
continu
chang
immunoregul
includ
exhaust
differ
compensatori
adapt
mechan
system
metabol
chang
make
clinic
cours
ms
hardli
predict
individu
patient
therefor
surpris
could
find
statist
signific
correl
titer
ab
mbp
ra
abzym
paramet
measur
sinc
patient
character
individu
combin
genet
environment
chronic
inflammatori
autoimmun
demyelin
neurodegen
andor
factor
gener
data
obtain
demonstr
mbphydrolyz
activ
intrins
properti
igg
deriv
csf
sera
ms
patient
igg
polyclon
may
consist
extrem
differ
repertoir
proteas
subfract
case
csf
sera
previous
shown
appear
abzym
specif
hydrolyz
mbp
among
earliest
clear
sign
autoimmun
reaction
number
autoimmun
diseas
titer
ab
mbp
autoantigen
yet
increas
significantli
correspond
rang
healthi
donor
therefor
detect
antimbp
ab
without
mbphydrolyz
activ
sera
csf
peopl
consid
addit
criterion
immunolog
paramet
earli
diagnost
ms
chemic
protein
protein
gsepharos
superdex
hr
column
sigma
ge
healthcar
use
purifi
human
mbp
contain
kda
form
rcmdt
moscow
russia
prepar
free
lipid
oligosaccharid
nucleic
acid
possibl
contamin
fifteen
consecut
ms
patient
women
men
mean
age
year
satisfi
criteria
definit
ms
accord
classif
mcdonald
admit
multipl
sclerosi
center
univers
ferrara
period
januari
octob
retrospect
select
studi
diseas
sever
score
ms
patient
time
sampl
collect
use
kurtzk
expand
disabl
statu
scale
edss
mean
entri
rang
clinic
cours
rr
pp
clinic
activ
relaps
time
sampl
mri
activ
presenc
gadolinium
enhanc
lesion
mri
examin
analyz
describ
previous
addit
use
control
seven
prepar
csf
blood
serum
healthi
donor
entri
none
patient
donor
fever
symptom
sign
acut
infect
moreov
time
sampl
collect
none
patient
receiv
potenti
diseasemodifi
therapi
month
studi
blood
csf
sampl
protocol
confirm
local
committe
medic
ethic
research
comitato
etico
della
provincia
di
ferrara
approv
studi
accord
helsinki
ethic
committe
guidelin
includ
written
consent
patient
confin
present
blood
csf
diagnost
possibl
diseas
scientif
purpos
protocol
approv
may
focus
creation
biolog
bank
csf
serum
sampl
relat
clinic
data
patient
ms
neurolog
diseas
includ
studi
potenti
marker
especi
protein
diagnost
prognost
signific
diseas
nervou
system
b
specif
antibodi
direct
antigen
potenti
exogen
andor
endogen
c
presenc
pathogen
mostli
virus
bacteria
associ
studi
pathogenesi
neurotransmitt
metabolit
e
studi
differ
properti
differ
marker
csf
serum
sampl
collect
steril
condit
store
aliquot
assay
cellfre
csf
sampl
obtain
centrifug
room
temperatur
specimen
taken
atraumat
lumbar
punctur
perform
purpos
diagnosi
absenc
contraind
serum
sampl
deriv
centrifug
blood
specimen
withdrawn
punctur
anterocubit
vein
time
csf
extract
pair
csf
serum
sampl
ms
patient
store
measur
exactli
condit
inform
consent
given
patient
inclus
studi
design
approv
region
committe
medic
ethic
research
csf
serum
igg
level
measur
immunochem
nephelometri
beckman
immag
immunochemistri
system
beckman
instrument
inc
fullerton
ca
usa
accord
procedur
salden
et
al
result
report
mean
least
three
independ
experi
sampl
analyz
error
valu
within
correl
coeffici
cc
set
differ
sampl
analyz
differ
sampl
analyz
student
ttest
consid
statist
signific
